These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 8642503

  • 1. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
    Yamada S, Yamada R, Ishii A, Ashikawa K, Kawamitsu H, Fujita K.
    J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503
    [Abstract] [Full Text] [Related]

  • 2. Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
    Daniel WC, Meidell RS, Hillis LD, Lange RA.
    Coron Artery Dis; 1996 Jan; 7(1):45-9. PubMed ID: 8773432
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.
    Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM.
    Thromb Haemost; 1991 Mar 04; 65(3):275-9. PubMed ID: 1904653
    [Abstract] [Full Text] [Related]

  • 5. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K, Beckmann R, Rauscha F, Probst P, Kaindl F, Binder BR.
    Z Kardiol; 1993 Mar 04; 82 Suppl 2():195-200. PubMed ID: 8328203
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
    Huber K, Rosc D, Resch I, Schuster E, Glogar DH, Kaindl F, Binder BR.
    Thromb Haemost; 1988 Dec 22; 60(3):372-6. PubMed ID: 3149044
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
    Cugno M, Cicardi M, Colucci M, Bisiani G, Merlini PA, Spinola A, Paonessa R, Agostoni A.
    Thromb Haemost; 1996 Aug 22; 76(2):234-8. PubMed ID: 8865537
    [Abstract] [Full Text] [Related]

  • 10. [t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction].
    Yamada S, Yamada R, Ishii A, Ashikawa K, Nakamura M, Sasamata M, Watanabe S.
    Rinsho Byori; 1990 Jul 22; 38(7):819-24. PubMed ID: 2119465
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
    Wojta J, Turcu L, Wagner OF, Korninger C, Binder BR.
    J Lab Clin Med; 1987 Jun 22; 109(6):665-71. PubMed ID: 3108431
    [Abstract] [Full Text] [Related]

  • 12. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
    Nagaizumi K, Kuroso K, Amano K, Sato T, Fukutake K, Fujimaki M.
    Rinsho Byori; 1994 Jul 22; 42(7):707-12. PubMed ID: 8065036
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M, Zegura B, Guzic-Salobir B, Keber I.
    Wien Klin Wochenschr; 2001 Feb 15; 113(3-4):113-8. PubMed ID: 11253736
    [Abstract] [Full Text] [Related]

  • 15. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?
    Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, Fortmann SP, Quertermous T, Hlatky MA, Atherosclerotic Disease, Vascular Function and Genetic Epidemiology Advance (ADVANCE) Study.
    Am Heart J; 2007 Dec 15; 154(6):1059-64. PubMed ID: 18035075
    [Abstract] [Full Text] [Related]

  • 16. Changes in plasma levels of tissue plasminogen activator and its inhibitor in aged myocardial infarction patients.
    Chen HZ, Jia HY, Song HY, Wang JY.
    Chin Med J (Engl); 1990 Jul 15; 103(7):541-5. PubMed ID: 2119970
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM, Koster RW, Burggraaf J, Huisman LG, Kluft C, Kroon R, Schoemaker RC, Cohen AF.
    Clin Pharmacol Ther; 1998 Jan 15; 63(1):39-47. PubMed ID: 9465840
    [Abstract] [Full Text] [Related]

  • 19. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Jan 15; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 20. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
    Hamsten A, Wiman B, de Faire U, Blombäck M.
    N Engl J Med; 1985 Dec 19; 313(25):1557-63. PubMed ID: 3934538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.